^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lonsurf (trifluridine/tipiracil)

    i
    Other names: TAS102, TAS-102, S 95005, FTD/TPI, S 95005/TAS-102, T15, T20, TAS 102, trifluridine AND tipiracil, T15/T20, TAS-102/S-95005, S-95005, S95005
    Company:
    Otsuka, Servier, TTY Biopharm
    Drug class:
    Thymidine phosphorylase inhibitor
    1d
    A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. (PubMed, Discov Oncol)
    In this retrospective, real-world study, the two regimens demonstrated comparable disease control, and the bi-weekly regimen appeared to be better tolerated, representing a reasonable potential alternative. Nevertheless, these findings should be interpreted as exploratory, and future prospective studies are warranted.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    3d
    A single-arm, multicenter, open-label clinical study to evaluate the efficacy and safety of trifluridine/tipiracil combined with tislelizumab and bevacizumab in patients with third-line or later locally advanced unresectable or metastatic colorectal cancer (ChiCTR2500112562)
    P=N/A, N=57, Recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Lonsurf (trifluridine/tipiracil)
    3d
    TAS-102 plus Fruquintinib or TAS-102 plus Fruquintinib in combination with Chidamide and Serplulimab as third-line and beyond treatment for metastatic colorectal cancer：A multicenter, randomized, two-arm clinical trial (ChiCTR2500115578)
    P4, N=64, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P4 trial
    |
    Fruzaqla (fruquintinib) • Epidaza (chidamide) • Lonsurf (trifluridine/tipiracil) • Hetronifly (serplulimab)
    3d
    Exploratory clinical study of fuquinitinib combined with TAS-102 as a second-line maintenance therapy for patients with metastatic colorectal cancer (ChiCTR2500112655)
    P4, N=40, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New P4 trial
    |
    RAS mutation
    |
    Lonsurf (trifluridine/tipiracil)
    3d
    Trifluridine-Tipiracil plus Fruquintinib vs Trifluridine-Tipiracil plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority trial (TAS-FUR) (ChiCTR2500112138)
    P4, N=236, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    3d
    Low-dose trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer: a multicenter, single-arm, phase 2 study (ChiCTR2500115479)
    P2, N=50, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    5d
    A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Anhui Provincial Cancer Hospital
    New trial
    |
    AiTan (rivoceranib) • Lonsurf (trifluridine/tipiracil)
    6d
    Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. (PubMed, J Comp Eff Res)
    Materials & An unanchored, matching-adjusted indirect comparison was conducted following a systematic literature review that identified the CORRECT trial (NCT01103323), which investigated regorafenib, and the RECOURSE trial (NCT01607957), which investigated trifluridine-tipiracil, as comparators for tucatinib in combination with trastuzumab. ORR also favored tucatinib in combination with trastuzumab across analyses. These data support that tucatinib in combination with trastuzumab is an effective therapy option in patients with previously treated mCRC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Stivarga (regorafenib) • Tukysa (tucatinib) • Lonsurf (trifluridine/tipiracil)
    7d
    Two cases of metastatic colorectal cancer in which epidermal growth factor receptor gene amplification benefited from panitumumab monotherapy. (PubMed, Int Cancer Conf J)
    After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy...After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery...As third-line therapy, he received pembrolizumab monotherapy...We encountered two patients with mCRC and EGFR gene amplification who responded to panitumumab monotherapy. EGFR gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of RAS status.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden)
    |
    TMB-H • EGFR amplification • RAS mutation • RAS wild-type
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • Teysuno (gimeracil/oteracil/tegafur)
    11d
    A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=464, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P3 trial
    |
    RAS mutation • RAS wild-type
    |
    Lonsurf (trifluridine/tipiracil)
    12d
    ALTAIR: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection (clinicaltrials.gov)
    P3, N=243, Completed, National Cancer Center Hospital East | Recruiting --> Completed
    Trial completion • Circulating tumor DNA
    |
    Signatera™
    |
    Lonsurf (trifluridine/tipiracil)